VYNE Therapeutics (VYNE) Misses Q1 EPS by 20c

VYNE Therapeutics (NASDAQ: VYNE) reported Q1 EPS of ($0.20). Revenue for the quarter came in at $200 thousand.

For earnings history and earnings-related data on VYNE Therapeutics (VYNE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral
• Wolfpack Research: 'we are short FTK because their $400m deal has been canceled'